1. Scrip
  2. >>Business

GSK Still Waiting For Infectious Disease Strategy To Move The Needle

Arexvy Set To Lead RSV Field, But Investors Want More

 
• By Andrew McConaghie

Ongoing Zantac litigation continues to cloud GSK’s share price, but it hopes a stream of infectious disease readouts will sway investor sentiment as it prepares for Arexvy’s launch.    

GSK

GSK has been a big pharma company in search of a fresh direction for some years, and its recent re-focus on infectious diseases – encompassing HIV treatment, vaccines and novel antimicrobials – has provided some clarity for investors. But there is little sign the markets are excited about its strategy and growth prospects, even after the company held a special capital markets day on 27 June to highlight its infectious diseases pipeline.

The company’s FTSE share price remained depressed the following day, and is currently down by 21% compared with 12 months ago, at £140 ($17.74). This is mainly due to ongoing uncertainty after lawsuits were launched last August claiming GSK’s old ulcer drug Zantac (ranitidine) had increased the risk of cancer in patients, which wiped billions off its share price and other implicated companies, such as Sanofi and Pfizer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.